There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ACADIA Pharmaceuticals (ACAD – Research Report), Progyny (PGNY – Research Report) and Protagonist Therapeutics (PTGX – Research Report) with bullish sentiments.
ACADIA Pharmaceuticals (ACAD)
In a report released today, Charles Duncan from Cantor Fitzgerald maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $42.00. The company’s shares closed last Tuesday at $26.36.
According to TipRanks.com, Duncan is a top 100 analyst with an average return of
ACADIA Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $35.18, a 35.1% upside from current levels. In a report issued on February 22, Mizuho Securities also maintained a Buy rating on the stock with a $40.00 price target.
See the top stocks recommended by analysts >>
Progyny (PGNY)
Cantor Fitzgerald analyst Sarah James maintained a Buy rating on Progyny yesterday and set a price target of $48.00. The company’s shares closed last Tuesday at $40.79.
According to TipRanks.com, James is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Progyny with a $46.09 average price target, implying a 14.1% upside from current levels. In a report issued on February 26, Leerink Partners also initiated coverage with a Buy rating on the stock with a $49.00 price target.
Protagonist Therapeutics (PTGX)
Capital One Financial analyst Tim Chiang maintained a Buy rating on Protagonist Therapeutics today and set a price target of $48.00. The company’s shares closed last Tuesday at $29.59, close to its 52-week high of $30.10.
According to TipRanks.com, Chiang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Protagonist Therapeutics with a $40.60 average price target, a 37.1% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $41.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACAD:
- Australian Stocks: Neuren’s (NEU) Daybue Sales Fail to Impress, Shares Plunge
- ACADIA Pharmaceuticals Inc. (ACAD) Q4 Earnings Cheat Sheet
- Neuren (NEU) Shares Plunge as Short Seller Targets Partner Acadia
- Acadia Pharmaceuticals down 3% after Culper short report
- Culper Research short Acadia, calls Daybue launch ‘total flop’
